Author: Mitchell Gaydash
Respiratory Toxicology for Pharmaceutical Development
May 6, 2020The Institute for In Vitro Sciences (IIVS) provides robust test systems and assays to detect the adverse effects of diverse materials, including pharmaceuticals targeting COVID-19. The IIVS Respiratory Toxicology Program offers testing services using cutting edge 3D pulmonary models - in addition to human 2D primary cells and lines - such as reconstructed human airways and precision-cut human lung slices that contain multiple cell types including immune competent macrophages. These systems allow the detection of acute toxic responses such as...
FDA Releases New Guidance Recommending Alternatives to LLNA
April 22, 2020FDA releases new guidance recommending the performance of alternative test methodologies in lieu of the murine-based Local Lymph Node Assay (LLNA) to assess skin sensitization potential for topically-applied drug products. This information can be found at https://www.fda.gov/media/135312/download, pages 7-8. IIVS offers multiple assays and provides guidance to companies and organizations interested in using non-animal approaches to evaluate this endpoint. Learn more about our skin sensitization testing capabilities at https://iivs.org/testing-services/assays/sensitization/ or contact us at clientservices@iivs.org....
Phototox and BCOP Russian Translations
February 25, 2020IIVS, in collaboration with EPAA, is pleased to announce that our training videos for eye irritation and phototoxicity are now available with Russian subtitles. To view subtitled versions in different languages including Chinese, Portuguese and Spanish, please visit our YouTube channel. ...